

Version history

Version	Release Date	What's new in this document
3.0	14 December 2021	<p>ES Parts for revision/ replacement</p> <ul style="list-style-type: none"> ● Responsiveness to magnitude and severity (C1): Updating of epidemiologic data ● Affordability and viability (C3): Updating of costing analysis for affordability and viability based on updates from DPCB ● Household financial impact (C4): Updated Cost of Illness Data from PhilHealth ● Responsiveness to Equity (C6): Updated evidence on responsiveness to equity with new clinical evidence <p>ES Parts for additional information</p> <ul style="list-style-type: none"> ● Clinical efficacy and safety (C2): Additional real world data on effectiveness over time and safety ● Social Impact (C5): Additional national survey results on vaccine preference, PhilHealth Circular 2021-0007. <p>Evidence parts that will remain valid</p> <ul style="list-style-type: none"> ● HTAC recommendation <p>Contents of V1 and V2 ES that are not mentioned here remain valid.</p>
2.0	25 June 2021	<p>ES Parts for revision/ replacement</p> <ul style="list-style-type: none"> ● Responsiveness to magnitude and severity (C1): Updating of epidemiologic data ● Affordability and viability (C3): Updating of costing analysis for affordability and viability based on updates from DPCB <p>ES Parts for additional information</p> <ul style="list-style-type: none"> ● Clinical efficacy and safety (C2): Additional real world data on effectiveness and safety ● Social Impact (C5): Additional national survey results on vaccine preference, PhilHealth Circular 2021-0007. <p>Evidence parts that will remain valid</p> <ul style="list-style-type: none"> ● HTAC recommendation ● Household financial impact

		<p>(C4)</p> <ul style="list-style-type: none">• Responsiveness to Equity (C6) <p>Contents of V1 ES that are not mentioned here remain valid.</p>
1.0	12 April 2021	- Initial release of HTAC recommendation

Rationale for updating the HTAC recommendation on *Sputnik V*

In lieu of evolving evidence on COVID-19, the HTAC releases its updated recommendations on the DOH financing for the emergency use of *Sputnik V*.

HTAC recommendation (as of 09 December 2021)

Based on the current information reviewed and presented in this updated evidence summary, the HTAC deems that there is no strong evidence to revise the recommendations dated 25 June 2021 on clinical efficacy and safety of *Sputnik V*. Furthermore, the relatively high cost of this vaccine, documented issues of delayed deliveries, and challenges experienced during roll out (e.g., stringent and longer time of preparation for the administration of the vaccine and decreased viability due to ambient air requirement) need to be considered in the procurement plans.